Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
A recent case report by Humphrey in the Journal of Urology offers information about a 67-year-old patient found to have a form of prostate cancer known as angiosarcoma of the prostate.
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: angiosarcoma, primary, sarcoma | 4 Comments »
We have now had the chance to look carefully through the new, patient-specific guidelines on prostate cancer issued by the National Comprehensive Cancer Network (NCCN) just before the Holidays. They are not perfect, but they are certainly a vast improvement over the NCCN’s first attempt.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Diagnosis, guideline, Management, NCCN, patient, risk | 16 Comments »
It has previously been proposed by some researchers that daily dosing with magnesium oxide (MgO) — alone or as part of an antiflatulent dietary regimen — can be used to reduce prostate motion (in combination with fiducial markers) during external beam radiation therapy for localized prostate cancer.
Filed under: Management, Treatment, Uncategorized | Tagged: antiflatulent, IMRT, magnesium, MgO, motion, oxide, radiation | Leave a Comment »
The “New” Prostate Cancer InfoLink is pleased to see that — here in the USA — the National Comprehensive Cancer Network (NCCN) has just issued a fully revised, new edition of the NCCN Guidelines for Patients™ for Prostate Cancer (Version 1.2011).
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: edition, guideline, NCCN, new, patient | 5 Comments »
A newly published mini-review in BJU International deals with the biologic and clinical significance of high-grade prostatic intraepithelial neoplasia (HG-PIN) as a sole finon an initial biopsy for risk of prostate cancer.
Filed under: Diagnosis, Management, Risk | Tagged: HG-PIN, high-grade, PIN, prostatic intraepithelial neoplasia | Leave a Comment »
In May last year (i.e., May 2010), the Prostate Cancer Foundation announced a partnership with Johns Hopkins and Cedars-Sinai to set up a national, proactive prostate cancer surveillance initiative. We reported this announcement … and then we heard no more.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active surveillance, National Proactive Surveillance Network, registry, trial | Leave a Comment »
When Paul VanDervelder was told his PSA had spiked, he did what many men do. He panicked! But then he did what he was trained to do as an investigative journalist. He investigated.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Diagnosis, PSA, risk | 7 Comments »
According to new data from a study at the University of Chicago, African-American males scheduled for a prostate biopsy are at greater risk for a positive diagnosis of cancer than white males and they also significantly underestimate their probability of a positive biopsy result.
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: belief, biopsy, ethnicity, outcome, race, risk | Leave a Comment »
According to a report from Prof. Thomas Aherling on the UroToday web site, there were three interesting presentations related to nerve-sparing surgery at the recent World Conference of Endourology and SWL, in Kyoto Japan.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: nerve-sparing, outcome, radical prostatectomy, sexual function, surgery | Leave a Comment »
Some readers may want to review the article on the Reuters web site entitled “Health panel takes heat on cancer screening advice.”
Filed under: Diagnosis, Risk | Tagged: screening, USPSTF | 8 Comments »
Many organizations develop guidelines for the prevention, diagnosis, and treatment of cancer (prostate cancer included). And the differences between these guidelines can be striking and controversial
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention | Tagged: American Cancer Society, guidelines | 2 Comments »
It appears that research funding of $80 million will again be directed for use to study prostate cancer through the Department of Defense’s Congressionally Directed Medical Research Program (DoD CDMRP) for the financial year 2012. This is a big and important “win” for prostate cancer research during a time of fiscal constraint.
Filed under: Uncategorized | Tagged: CDMRP, research | 3 Comments »
An article published on-line in BJU International suggests that there are limits to the degree to which PSA density is accurately predictive of risk for upstaging of clinically localized prostate cancer.
Filed under: Diagnosis, Management, Risk | 6 Comments »
The following article was just published by Ranjana Srivastava, MD, in The New England Journal of Medicine under the title “Dealing with uncertainty in a time of plenty.”
Filed under: Living with Prostate Cancer, Uncategorized | Tagged: communication, doctor, patient | 4 Comments »
Now here’s a new perspective on the value of widespread prostate cancer screening from one of the founders of Prostate Cancer Awareness Week — Dr. David Crawford of the University of Colorado Health Science Center in Denver, CO (who is also the Chairman of the Prostate Conditions Education Council):
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: elderly, screening, testing, value | 2 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site